Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality

被引:132
作者
Verbrugge, Frederik H. [1 ,2 ,3 ]
Omote, Kazunori [1 ]
Reddy, Yogesh N., V [1 ]
Sorimachi, Hidemi [1 ]
Obokata, Masaru [1 ]
Borlaug, Barry A. [1 ]
机构
[1] Mayo Clin, Dept Cardiovasc Dis, Rochester, MN 55905 USA
[2] Univ Hosp Brussels, Ctr Cardiovasc Dis, Brussels, Belgium
[3] Hasselt Univ, Fac Med & Life Sci, Biomed Res Inst, Hasselt, Belgium
基金
美国国家卫生研究院;
关键词
Diastolic heart failure; Exercise tolerance; Mortality; Natriuretic peptides; Obesity; AMERICAN SOCIETY; EUROPEAN ASSOCIATION; ECHOCARDIOGRAPHY; RECOMMENDATIONS; DYSFUNCTION; EXERCISE; UPDATE;
D O I
10.1093/eurheartj/ehab911
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background A substantial proportion of patients with heart failure (HF) with preserved ejection fraction (HFpEF) present with normal natriuretic peptide (NP) levels. The pathophysiology and natural history for this phenotype remain unclear. Methods and results Consecutive subjects undergoing invasive cardiopulmonary exercise testing for unexplained dyspnoea at Mayo Clinic in 2006-18 were studied. Heart failure with preserved ejection fraction was defined as a pulmonary arterial wedge pressure (PAWP) >= 15 mmHg (rest) or >= 25 mmHg (exercise). Patients with HFpEF and normal NP [N-terminal of the pro-hormone B-type natriuretic peptide (NT-proBNP) < 125 ng/L] were compared with HFpEF with high NP (NT-proBNP >= 125 ng/L) and controls with normal haemodynamics. Patients with HFpEF and normal (n = 157) vs. high NP (n = 263) were younger, yet older than controls (n = 161), with an intermediate comorbidity profile. Normal NP HFpEF was associated with more left ventricular hypertrophy and worse diastolic function compared with controls, but better diastolic function, lower left atrial volumes, superior right ventricular function, and less mitral/tricuspid regurgitation compared with high NP HFpEF. Cardiac output (CO) reserve with exercise was preserved in normal NP HFpEF [101% predicted, interquartile range (IQR): 75-124%], but this was achieved only at the cost of higher left ventricular transmural pressure (LVTMP) (14 +/- 6 mmHg vs. 7 +/- 4 mmHg in controls, P < 0.001). In contrast, CO reserve was decreased in high NP HFpEF (85% predicted, IQR: 59-109%), with lower LVTMP (10 +/- 8 mmHg) compared with normal NP HFpEF (P < 0.001), despite similar PAWP. Patients with high NP HFpEF displayed the highest event rates, but normal NP HFpEF still had 2.7-fold higher risk for mortality or HF readmissions compared with controls (hazard ratio: 2.74, 95% confidence interval: 1.02-7.32) after adjusting for age, sex, and body mass index. Conclusion Patients with HFpEF and normal NP display mild diastolic dysfunction and preserved CO reserve during exercise, despite marked elevation in filling pressures. While clinical outcomes are not as poor compared with patients with high NP, patients with normal NP HFpEF exhibit increased risk of death or HF readmissions compared with patients without HF, emphasizing the importance of this phenotype. Key question What is the prognosis of patients with heart failure and preserved ejection fraction (HFpEF) who have normal natriuretic peptide (NP) levels? How does this group present in terms of cardiac structure and function, and haemodynamics at rest and during exercise? Key finding Patients with HFpEF and normal NP levels have increased mortality and heart failure readmissions compared with subjects with non-cardiac dyspnoea. Heart failure and preserved ejection fraction with elevated vs. normal NP levels is associated with worse right ventricular function, more secondary valve regurgitation, and impaired cardiac output reserve. Take-home message A considerable number of patients with HFpEF present with normal NP levels. Those patients exhibit increased morbidity and mortality in comparison with patients without heart failure, emphasizing the importance of this phenotype.
引用
收藏
页码:1941 / 1951
页数:11
相关论文
共 31 条
  • [1] Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction
    Abudiab, Muaz M.
    Redfield, Margaret M.
    Melenovsky, Vojtech
    Olson, Thomas P.
    Kass, David A.
    Johnson, Bruce D.
    Borlaug, Barry A.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2013, 15 (07) : 776 - 785
  • [2] Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction
    Anand, Inder S.
    Claggett, Brian
    Liu, Jiankang
    Shah, Amil M.
    Rector, Thomas S.
    Shah, Sanjiv J.
    Desai, Akshay S.
    O'Meara, Eileen
    Fleg, Jerome L.
    Pfeffer, Marc A.
    Pitt, Bertram
    Solomon, Scott D.
    [J]. JACC-HEART FAILURE, 2017, 5 (04) : 241 - 252
  • [3] Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction Findings From the I-PRESERVE Trial
    Anand, Inder S.
    Rector, Thomas S.
    Cleland, John G.
    Kuskowski, Michael
    McKelvie, Robert S.
    Persson, Hans
    McMurray, John J.
    Zile, Michael R.
    Komajda, Michel
    Massie, Barry M.
    Carson, Peter E.
    [J]. CIRCULATION-HEART FAILURE, 2011, 4 (05) : 569 - 577
  • [4] Prevalence, Clinical Phenotype, and Outcomes Associated With Normal B-Type Natriuretic Peptide Levels in Heart Failure With Preserved Ejection Fraction
    Anjan, Venkatesh Y.
    Loftus, Timothy M.
    Burke, Michael A.
    Akhter, Nausheen
    Fonarow, Gregg C.
    Gheorghiade, Mihai
    Shah, Sanjiv J.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2012, 110 (06) : 870 - 876
  • [5] Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction The VITALITY-HFpEF Randomized Clinical Trial
    Armstrong, Paul W.
    Lam, Carolyn S. P.
    Anstrom, Kevin J.
    Ezekowitz, Justin
    Hernandez, Adrian F.
    O'Connor, Christopher M.
    Pieske, Burkert
    Ponikowski, Piotr
    Shah, Sanjiv J.
    Solomon, Scott D.
    Voors, Adriaan A.
    She, Lilin
    Vlajnic, Vanja
    Carvalho, Francine
    Bamber, Luke
    Blaustein, Robert O.
    Roessig, Lothar
    Butler, Javed
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (15): : 1512 - 1521
  • [6] Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction
    Bishu, Kalkidan
    Deswal, Anita
    Chen, Horng H.
    LeWinter, Martin M.
    Lewis, Gregory D.
    Semigran, Marc J.
    Borlaug, Barry A.
    McNulty, Steven
    Hernandez, Adrian F.
    Braunwald, Eugene
    Redfield, Margaret M.
    [J]. AMERICAN HEART JOURNAL, 2012, 164 (05) : 763 - U171
  • [7] The Role of the Pericardium in Heart Failure Implications for Pathophysiology and Treatment
    Borlaug, Barry A.
    Reddy, Yogesh N., V
    [J]. JACC-HEART FAILURE, 2019, 7 (07) : 574 - 585
  • [8] Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction
    Borlaug, Barry A.
    Kane, Garvan C.
    Melenovsky, Vojtech
    Olson, Thomas P.
    [J]. EUROPEAN HEART JOURNAL, 2016, 37 (43) : 3294 - 3302
  • [9] Exercise Hemodynamics Enhance Diagnosis of Early Heart Failure With Preserved Ejection Fraction
    Borlaug, Barry A.
    Nishimura, Rick A.
    Sorajja, Paul
    Lam, Carolyn S. P.
    Redfield, Margaret M.
    [J]. CIRCULATION-HEART FAILURE, 2010, 3 (05) : 588 - +
  • [10] The Universal Definition of Heart Failure: Perspectives from Diverse Stakeholders
    Mentz, Robert J.
    Lala, Anuradha
    [J]. JOURNAL OF CARDIAC FAILURE, 2021, 27 (04) : 386 - 386